The receptor for EGF is a 175,000 mol. wt membrane protein which consists of an extracellular EGF-binding domain, a short hydrophobic transmembrane segment, and an intracellular domain which possesses a ligand stimulated tyrosine kinase activity (Carpenter, 1983; Downward et al., 1984a) . The receptor can phosphorylate a number of protein substrates, in addition to mediating autophosphorylation of three tyrosine residues located close to its own carboxy terminus (Downward et al., 1984b; Gullick et al., 1985) . The role of the tyrosine kinase activity in signal transduction is not clear, but it is presently the only known ligandstimulated activity of the receptor protein and therefore is likely to be involved in the transmembrane signaling process.
Study of the structure and function of the EGF receptor in tumours was stimulated by the observation that the v-erb-B oncogene of avian erythroblastosis virus, which can cause erythroblastosis and sarcomas in infected chickens, is derived from the chicken EGF receptor gene. (Downward et al., 1984a; Olofsson et al., 1986) . The transforming protein produced from the v-erb-B oncogene is a doubly truncated chicken EGF receptor which lacks virtually the entire extracellular ligand binding domain as well as the most Cterminal autophosphorylation site (Downward et al., 1984a,b; ) . It has been suggested that the loss of the ligand binding domain of the receptor may leave the tyrosine kinase of v-erb-B in a constitutively active form (Gilmore et al., 1985; Kris et al., 1985) . Since the EGF receptor kinase catalyses the transfer of phosphate groups to tyrosine residues of substrate proteins, it would seem likely that the amount of tyrosine kinase activity would be important in influencing the growth rate of cells. For instance, an abnormal EGF receptor with increased tyrosine kinase activity might cause rapid cell division. We therefore isolated EGF receptors from the tumour specimens and analyzed their enzyme activity by their ability to become radioactively labeled with 32P by autophosphorylation.
The loss of the most C-terminal autophosphorylation site, the major site used in vivo, might also be an important structural change leading to functional abnormalities of the v-erb-B oncogene protein (Downward et al., 1984b) . Other oncogene proteins, such as those of v-fms (Coussens et al., 1986 ) and v-src (Takeya et al., 1983) , also differ from their proto-oncogene counterparts by the loss of a C-terminal tyrosine. Phosphorylation of a tyrosine in the C-terminal area of the normal cellular counterpart of these proteins may play a role in inhibiting receptor kinase activity. We therefore examined the EGF receptor from one bladder tumour with high levels of EGF receptors (high levels are required to do the study) to see both whether this site was present in the protein and whether it was utilized normally as a site of autophosphorylation.
Although . Squamous cell carcinomas from various primary sites Cowley et al., 1984) have been found to express relatively high levels of EGF receptors, as have some gliomas (Libermann et al., 1984a) , gynaecological tumours (Gullick et al., 1986) , breast tumours (Fitzpatrick et al., 1984; Perez et al., 1984; Sainsbury et al., 1985) , and sarcomas (Gusterson et al., 1985) .
Some squamous cell carcinoma cell lines with high EGF receptor expression have amplification of the EGF receptor gene (Merlino et al., 1984; Merlino et al., 1985; Yamamoto et al., 1986; Ozanne et al., 1986) . These include the well studied vulval carcinoma cell line A431 (Merlino et al., 1984) . Amplification has also been described in a breast carcinoma cell line (Filmus et al., 1985) and in primary specimens of some gliomas (Libermann et al., 1984b) and squamous cell carcinomas Ozanne et al., 1986; Hunts et al., 1985) . Although some bladder tumours have been reported to have high levels of EGF receptor protein expression (Neal et al., 1985; , the structure of the EGF receptor gene in bladder tumours has not been studied.
Since a previous immunohistochemical study suggested that EGF receptors were found significantly more often in invasive and poorly differentiated tumours than in superficial and moderately differentiated tumours (Neal et al., 1985) (Waterfield et al., 1982) used at a concentration of 0.01 mgml-1, and F4, a Mab to the intracellular domain (Gullick et al., 1986) used at a concentration of 0.05mgml-1. These antibodies to different domains of the receptor were used to screen for truncated EGF receptor species analagous to the v-erb-B protein.
Alkaline phosphatase/anti-alkaline phosphatase (APAAP) complexes were used in an unlabeled antibody bridge technique as described previously (Cordell et al., 1984) . A control tissue, squamous cell epithelium from the oral mucosa, was used to ensure that the same intensity of staining was achieved with both Mabs. The control tissue was also used to standardize the level of antibody staining, the staining of the basal cells of the oral mucosal epithelium being defined as weak.
EGF receptors were isolated from frozen samples of bladder tumours by immunoprecipitation and their ability to autophosphorylate assayed as described previously (Gullick et al., 1986) . Using methods described in detail elsewhere (Downward et al., 1984b) , EGF receptor protein was isolated from one of the tumours and subjected to tryptic phosphopeptide mapping by HPLC to determine whether all three sites of autophosphorylation were present and utilized in receptor catalyzed phosphorylation.
Southern blot analysis was performed to ascertain whether amplification or rearrangement of the EGF receptor gene was present (Maniatis et al., 1982) . The cDNA probe used in Southern blot analysis, 64.1, corresponded to most of the extracellular domain, all of the transmembrane region, and a short sequence of the intracellular domain. (Haley et al., 1987) .
Results

Immunocytochemistry
Thirty-one tumours were evaluated by immunocytochemistry for their levels of EGF receptor protein expression using the two antibodies to the EGF receptor. Six samples of normal bladder or ureter urothelium showed very weak staining which was confined to the basal layer of the urothelium. We graded as positive those tumours that expressed EGF receptor levels that were higher than that seen in normal urothelium; that is, weak, moderate or strong. Weak staining was further defined as being equal to the staining of the cells in the basal layer of the oral mucosal control tissue. Heterogeneity of staining was observed in 6 of the 11 positive tumours. This took the form of weaker staining of the 20-30% of the cells comprising the inside of masses of tumour cells. Otherwise, the staining of tumour cells was virtually homogenous.
The immunocytochemical data (Table I) shows that there was little disparity in the results obtained with the monoclonal antibodies to the extracellular domain (EGFR1) and the cytoplasmic region (F4) in any individual tumour specimen. In particular, there were no tumours with significant F4 staining and negative staining with EGFR1, which might have indicated the presence of truncated receptors. Our results using Mab EGFR1 showed a significant correlation between tumours that were positive for EGF receptors and invasive stage (P=0.01) and poor differentiation (P=0.005) ( Table II) . The data using the F4 Mab shows a similar trend that did not reach statistical significance in the small group of tumours studied (Table II) . Figure 1 and the results from all 28 specimens examined are given in Table I They showed the same pattern of labeled peptides with utilization of all three of the previously identified autophosphorylation sites to the same extent (Figure 2) . The phosphopeptide map of A431 cells is identical to that of EGF receptors from a normal tissue (placenta) and thus served as a control (Downward et al., 1984a) .
EGF receptor gene analysis The EGF receptor gene was analyzed by Southern blotting using DNA isolated from 29 tumours (in one case an inadequate amount of DNA was obtained, and one other specimen gave only degraded DNA despite repeated attempts at isolation). The EGF receptor gene was found to be amplified -8-10 times without apparent rearrangement in bladder tumour no. 11IFigure 3, lane 11). This tumour was previously shown to have a high level of receptor expression by both immunocytochemical and autophosphorylation studies. In all other cases, the gene was present in a single copy without evidence of rearrangement.
Discussion
Urine bathing the bladder mucosa contains epidermal growth factor (EGF) in ng ml-I concentrations which are substantially higher than the pg ml-1 concentrations usually found in serum (Oka & Orth, 1983; Mattila et al., 1986 ).
An abnormal increase in the number of EGF receptors on cells in this environment might lead to an increased Track labelled A was loaded with 2.5pg A431 cell DNA and track labelled P with lOpg placental DNA. Tracks 1-12 represent lOg DNA from tumours 1-12 respectively. Tumour 9 gave only degraded DNA on several attempts at DNA isolation. The autoradiograph was exposed for 48 h at -70'C using Kodak XAR5 film.
responsiveness to EGF and to stimulation of growth. Alternatively, the production of mutant receptors with an enhanced response to EGF, or with no response to EGF, could result in profound abnormalities in the control of urothelial cell growth. There is as yet no direct evidence that implicates EGF in urine as a critical element for the growth of bladder tumours, but the higher EGF levels found there suggested that the study of EGF receptors in bladder tumours might be productive.
Recent literature has suggested that prognostic information may be derived from the study of protooncogenes in some tumours. For example, N-myc gene amplification in neuroblastomas (Seeger et al., 1985; Brodeur et al., 1986) , ras expression in prostate carcinomas (Viola et al., 1986) , and amplification of the EGF receptor related HER-2 gene in breast carcinomas (Slamon et al., 1987) all have been shown to have prognostic implications for patients with those tumours. A marker which could similarly predict the behaviour of bladder tumours would be very valuable to oncologists and urologists. Neal et al. (1985) suggested that EGF receptor expression was related to the pathologic characteristics of malignant bladder tumours and our data are consistent with that finding.
In this study the immunocytochemistry data using the EGFR1 Mab, the same antibody used by Neal et al. (1985) , showed a statistically significant correlation between positive tumours and bladder carcinoma stage and grade. Statistically significant correlations with tumour stage and grade were not seen using the F4 Mab, although a trend was clearly present. The affinity of the F4 Mab for the EGF receptor in solution is -5-10 fold lower than the EGFR1 Mab and thus it was used at five times the concentration of the EGFR1 Mab to obtain staining of the same intensity from a control oral mucosal tissue. In future studies we would recommend using the EGFR1 Mab because of its greater sensitivity.
This study was different from that of Neal et al. (1985) in that a more sensitive immunocytochemical technique (APAAP) was used. This resulted in very weak staining of normal bladder mucosa and allowed us to grade as positive only those tumours that were more strongly stained than the normal mucosa. The previous study used an indirect immunocytochemistry technique and found normal bladder mucosa to be negative. Furthermore we think that the use of one control tissue (oral mucosa) throughout the study reduced the subjectivity inherent in comparing tumours stained on different days.
The F4 Mab was principally employed to determine whether bladder tumours expressed a large population of truncated EGF receptors analogous to the v-erb-B protein. This was not found to be the case since differences in staining of individual tumours were small (Table I ). The presence of low concentrations of truncated receptors cannot be totally excluded, but since EGF receptor gene structure was normal on Southern blots this is unlikely.
The autophosphorylation studies demonstrated that the EGF receptor protein identified immunologically was functional at least in its ability to mediate autophosphorylation, and that abnormal sized EGF receptors were not produced in the tumours. The percentage of tumours with demonstrable autophosphorylation activity was not appreciably different in tumours of advanced stage and grade than in those which were histologically less aggressive, although tumours with higher levels of autophosphorylation activity were more common in the poorly differentiated or invasive tumour groupings. The autophosphorylation assay in our hands was not as precise a technique as immunocytochemistry and this may explain differences in the results obtained with the two methods. In the one case where the bladder tumour was rich enough in receptor protein to be analyzed, the EGF receptors were shown to utilize the three major autophosphorylation sites normally.
Receptor gene amplification was found in only one tumour which also had very high levels of EGF receptor protein. Major deletions, truncation or rearrangement were not seen in the area of the gene probed. The gene structure of another proto-oncogene, the c-H-ras-1 gene, which has been shown by transfection assays to be present as a transforming oncogene in some bladder carcinoma cell lines and primary tumours (Fujita et al., 1984) , has also been studied in bladder tumours. Amplification and rearrangement of this gene has been reported in one case of squamous cell carcinoma of the bladder (Hayashi et al., 1983) . However a study of 15 unselected bladder tumours found no amplification or rearrangement of the c-H-ras-1 gene, suggesting that, just as in the case of the EGF receptor gene, its amplification is not a common event (Malone et al., 1985) .
Point mutations such as those shown to activate the ras (Sukumar et al., 1983) and neu (Bergmann et al., 1986) oncogenes would not be detected by the methods used in this study and thus we cannot conclude that the EGF receptor gene in these tumours is entirely normal. Some recent reports (e.g. Reidel et al., 1987) suggest that there may be as yet unidentified point mutations in the v-erb-B oncogene that are important to its function. If future work identifies specific amino acid differences between the chicken EGF receptor and v-erb-B, this may provide the means for further evaluation of the EGF receptors in bladder tumours which, from this analysis, appear to be normal in structure and function.
Further work is needed to determine if EGF receptor expression in bladder tumours is directly related to prognosis. We have planned prospective studies utilizing immunocytochemistry with Mab EGFR1 to evaluate recurrence rates and death rates in patients with tumours of different stage, grade, and levels of EGF receptor expression.
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